Xencor (NASDAQ:XNCR) Stock Passes Below Two Hundred Day Moving Average – What’s Next?

Shares of Xencor, Inc. (NASDAQ:XNCR) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $12.41 and traded as low as $11.76. Xencor shares last traded at $11.99, with a volume of 471,276 shares traded.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Cantor Fitzgerald boosted their price target on shares of Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Wedbush reiterated an “outperform” rating and issued a $26.00 target price on shares of Xencor in a research report on Thursday, November 6th. JPMorgan Chase & Co. lowered their price target on Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Barclays upped their price objective on Xencor from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.88.

Xencor Trading Down 1.0%

The firm has a fifty day moving average of $14.95 and a two-hundred day moving average of $12.41. The company has a market capitalization of $856.21 million, a PE ratio of -6.77 and a beta of 0.98.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.64. Xencor had a negative return on equity of 20.44% and a negative net margin of 87.14%.The firm had revenue of $21.00 million during the quarter, compared to the consensus estimate of $29.73 million. During the same quarter in the previous year, the company posted ($0.71) earnings per share. The business’s revenue was up 18.0% on a year-over-year basis. On average, equities analysts expect that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insider Activity

In other Xencor news, CEO Bassil I. Dahiyat sold 114,377 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $15.71, for a total transaction of $1,796,862.67. Following the completion of the transaction, the chief executive officer owned 466,635 shares of the company’s stock, valued at $7,330,835.85. This represents a 19.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP John R. Desjarlais sold 73,367 shares of Xencor stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $15.72, for a total value of $1,153,329.24. Following the completion of the sale, the vice president owned 236,574 shares in the company, valued at approximately $3,718,943.28. This represents a 23.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 5.23% of the company’s stock.

Institutional Trading of Xencor

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hantz Financial Services Inc. increased its position in Xencor by 209.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 2,156 shares during the period. GAMMA Investing LLC boosted its stake in shares of Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in shares of Xencor during the third quarter valued at about $44,000. Federated Hermes Inc. raised its stake in Xencor by 114.3% in the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 2,105 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in Xencor by 85.5% in the third quarter. Nisa Investment Advisors LLC now owns 5,260 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 2,424 shares during the period.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.